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We performed a whole-genome association study of human immunodeficiency virus type 1 (HIV-1) set point
among a cohort of African Americans ( ), and an intronic single-nucleotide polymorphism (SNP) innp 515
the HLA-B gene showed one of the strongest associations. We use a subset of patients to demonstrate that
this SNP reflects the effect of the HLA-B*5703 allele, which shows a genome-wide statistically significant
association with viral load set point ( ). These analyses therefore confirm a member of the HLA-10Pp 5.6 10
B*57 group of alleles as the most important common variant that influences viral load variation in African
Americans, which is consistent with what has been observed for individuals of European ancestry, among
whom the most important common variant is HLA-B*5701.
A recent genome-wide association study performed
among individuals of European ancestry identified 2
polymorphisms associated with human immunodefi-
ciency virus type 1 (HIV-1) load at set point and a third
set of polymorphisms associated with a simple measure
of disease progression [1]. One variant that was found
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to be associated with set point (rs2395029) encodes a
nonsynonymous change in the HCP5 gene and is also
a tag for HLA-B*5701, which has been shown to be
associated with improved early outcomes after exposure
to HIV-1 [2, 3]. The other variant that is associated
with set point (rs9264942) is 35 kilobases upstream of
the HLA-C locus and appears to be tagging a causa-
tive variant or variants. A third variant (rs9261174) as-
sociated with disease progression is located near the
ZNRD1 gene in the major histocompatibility complex
(MHC) region, although functional work on this gene
has not yet identified a causal variant. Together, these
variants are able to explain ∼14% of the observed var-
iation in outcome after HIV-1 exposure.
A follow-up study investigated the impact of these
same single-nucleotide polymorphisms (SNPs) on an
HIV-1–positive African American cohort ( )np 121
[4]. As was seen in individuals of European ancestry,
the HLA-C–associated variant (rs9264942) was again
found to be associated with viral load, with the C “high-
expression” allele leading to lower viral load. Although
no association was observed with the G allele of
rs2395029, this allele is rare in African Americans; in
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Table 1. Baseline Characteristics of Participants in the Multicenter AIDS Cohort Study (MACS)
and Department of Defense (DoD) Cohorts ( )np 515
Variable MACS Cohort DoD Cohort
No. of participants 118 397
Male sex, % 100 94
Mean age at seroconversion (range), years 32.0 (20–55) 27.5 (18–55)
Mean viral load set point (range), log10 copies/mL 4.00 (1.91–6.01) 4.12 (1.91–5.97)
Mean year of seroconversion (range) 1991 (1984–2005)a 1996 (1986–2003)
Minor allele frequency for rs2523608, % 39.4b 35.4
HLA-B*5703 carriers, % 7.5b 8.3
Samples measured with Illumina Bead Chip, %
1M 53 77
1M-Duo 37 23
550K 10 0
a Serocoversion date was available for only 52 of the 118 MACS participants.
b comparing MACS with DoD cohort.P 1 .05
people of European ancestry, the allele is in linkage disequilib-
rium with HLA-B*5701, which is also rare in people of African
descent. However, an analysis of the HLA-B alleles present in
the region showed an association between HLA-B*57 (com-
prised predominantly of HLA-B*5703) and favorable virologic
outcome.
Although the study described above [4] and others [5, 6]
have assessed the impact of variants in African Americans that
were first identified in patients of European ancestry, to our
knowledge there has not yet been any genome-wide investi-
gation of the most important common variants that influence
viral load in patients of primarily African ancestry. Here, we
present the first genome-wide association study of determinants
of HIV-1 control performed among a non-European popula-
tion. Using a cohort of African American individuals (np
), we sought to evaluate the associations previously reported515
and to discover novel or population-specific genetic variants
that are associated with HIV-1 control.
METHODS
Samples. This study included HIV-1–infected African Amer-
ican adult participants enrolled in either the United States mil-
itary Department of Defense Human Immunodeficiency Virus
Natural History Study (DoD HIV NHS) or the Multicenter
AIDS Cohort Study (MACS). This study was approved by lo-
cal institutional review boards, and each participant provided
written, informed consent.
The DoD HIV NHS (http://www.idcrp.org/hiv-natural-history
-study.html) is an ongoing, prospective, continuous-enrollment
cohort study of consenting military personnel and beneficiaries
with HIV infection and includes participants from the Army,
Navy/Marines, and Air Force and their dependents. Since 1985,
routine HIV testing (by enzyme-linked immunosorbent assay
and confirmatory Western blot analysis) has been used to ex-
clude HIV-infected persons from enlisting for military service
or from overseas deployment. Periodic testing among active
duty members occurs every 1–5 years, resulting in a defined
seroconversion window for incident HIV infection. Participants
with HIV infection are referred to military medical centers,
where they receive evaluation and ongoing care and are invited
to enroll as participants in the DoD HIV NHS.
Those who consent to enroll in the DoD HIV NHS are seen
every 6 months by an HIV specialist as part of the study, in
addition to receiving routine clinical care. Data are collected
on demographic characteristics, markers of HIV disease pro-
gression, medication use, and clinical events with medical rec-
ord confirmation. Cells, plasma, and serum are collected at
each visit and stored in a central repository.
Information was extracted from the database on HIV-in-
fected African American individuals with 4 years between
their last negative and first positive HIV test results, at least 5
million cells stored in the repository, and either 1 viral load
measurement taken 3–12 months after seroconversion (np
) or 2 viral load measurements taken within 3 months to140
3 years after seroconversion ( ). Ethnicity was self-iden-np 347
tified. The seroconversion date was estimated as the midpoint
between the last negative and first positive HIV test results.
The MACS (http://www.statepi.jhsph.edu/macs/macs.html)
is an ongoing prospective study of the natural and treated his-
tories of HIV-1 infection among men who have sex with men
that is conducted by sites located in Baltimore, Chicago, Pitts-
burgh, and Los Angeles. A total of 6973 men have been enrolled;
3427 participants were HIV-seronegative at study entry and
were tested for seroconversion semiannually by means of en-
zyme-linked immunosorbent assay, with positive test results
confirmed by Western blot analysis. Of the seroincident par-
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Table 2. Variants Most Strongly Associated with Set Point in African Americans ( )np 515
SNP Rank Chromosome P Closest gene Type Frequency
rs454422 1 20 61.49 10 MCM8 Intronic 0.258
rs2523608 2 6 62.29 10 HLA-B Intronic 0.366
rs6948404 3 7 63.41 10 AOAH Intronic 0.074
rs558718 4 19 63.71 10 EVI5L Intronic 0.110
rs1357339 5 11 64.58 10 NA Intergenic 0.035
rs1413191 6 13 64.61 10 GPC5 Intronic 0.181
rs236104 7 20 66.72 10 MCM8 Intronic 0.252
rs7998089 8 13 67.41 10 GPC5 Intronic 0.191
rs2593321 9 3 67.70 10 AC023798.16a Intergenic 0.231
rs6492611 10 13 67.97 10 GPC5 Intronic 0.208
rs4872511 11 8 69.25 10 PPP3CC Downstream 0.011
rs2280890 12 8 69.25 10 SORBS3 Upstream 0.011
rs2789066 13 6 69.41 10 RP11-100A16.1a Upstream 0.127
rs430374 14 18 51.01 10 ST8SIA5 Intergenic 0.196
rs9910853 15 17 51.07 10 ZNF652 Intronic 0.085
rs762372 16 21 51.10 10 NA Intergenic 0.470
rs236106 17 20 51.23 10 MCM8 Intronic 0.252
rs1348478 18 5 51.26 10 PRR16 Intergenic 0.337
rs12103812 19 17 51.34 10 ZNF652 3′ UTR 0.084
rs8014482 20 14 51.44 10 AL355773.4-1a Intergenic 0.256
NOTE. Age, sex, cohort, and 1 statistically significant EIGENSTRAT axis were used as covariates. NA, not applicable;
SNP, single-nucleotide polymorphism; UTR, untranslated region.
a Listed as transcript in Ensembl (July 2009).
ticipants, African Americans with available DNA and viral load
data from before treatment initiation were selected for inclusion
in the current study.
Other cohorts referenced in this analysis include HIV-1–
infected adult participants of European ancestry in a study
performed by the European Center for HIV/AIDS Vaccine Im-
munology (Euro-CHAVI) and MACS participants who were
included in a previous whole-genome association study (np
) [7]. The Euro-CHAVI cohort represents a consortium2362
of 8 European cohorts and 1 Australian cohort of patients who
agreed to participate in the Host Genetic Core initiative of the
Center for HIV/AIDS Vaccine Immunology (CHAVI).
Genotyping. All samples were genotyped using Illumina
HumanHap 1M ( ), HumanHap 1M-Duo ( ),np 368 np 135
or Illumina HumanHap 550K ( ) Bead Chips. All sam-np 12
ples were brought into a single BeadStudio file using the stan-
dard Illumina cluster file. For quality control purposes, any
sample that had very low intensity or a very low call rate with
Illumina cluster (!99%) was deleted. All SNPs that had a call
frequency of !99% were put into a filter and reclustered (ex-
cluding those on the X chromosome). The reclustering step
created SNP calling errors, but the following procedures were
used to prevent the errant calls from being released in the final
report: (1) the SNPs with a cluster separation value of !0.3
were deleted, and (2) any SNPs with a Het Excess value (an
indicator of the quantity of excess heterozygote calls relative to
expectations) between 1.0 and 0.1 or between 0.1 and 1.0
were deleted. The filter was then released, and any SNP with
a call frequency of !99% was deleted. These procedures resulted
in a success rate of genotyping calls ranging from 99.20% to
99.999%, and 1,212,217 SNPs were included in the analysis.
Ten samples were excluded because of insufficient call rate.
Specification of sex check, cryptic relatedness check, low mi-
nor allele frequency check, Hardy-Weinberg equilibrium check,
and a recheck of the genotyping quality were all performed as
described elsewhere [1], and no samples were omitted at these
steps. A total of 129,723 SNPs were dropped because of a low
minor allele frequency. We also required that all SNPs included
in the study were successfully genotyped in at least 50% of the
samples; hence, 202,676 SNPs were dropped at this point, many
of which were those not genotyped on all of the chips.
We used the Illumina 1M and 1M-Duo Bead Chip data as
input into the PennCNV program [8], which allowed us to
look at deletions (0 or 1 copy) compared with wild types (2
copies) and duplications (3 or 4 copies) compared with wild
types (2 copies). Because of the complications of hemizygosity
in males and X chromosome inactivation in females, this anal-
ysis was restricted to autosomes. In addition, to ensure that we
worked with high-confidence copy number variations (CNVs),
we excluded any CNV for which the difference in the log like-
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Figure 1. Distribution of mean human immunodeficiency virus type 1 (HIV-1) set point according to patient genotype. The direction of the effect of
the rs2523608 genotype is consistent in African American patients (A) and European patients (B). Patients with HLA-B*5703 have a lower HIV-1 set
point (C). VL, viral load.
lihood between the most likely copy number state and the less
likely copy number state was !10 (generated using the “conf”
function in PennCNV). We limited our analysis to CNVs that
occurred in at least 3 people (minor allele frequency, 10.003).
Further quality control thresholds in PennCNV that were used
are detailed in Ge et al [9]. In this analysis, 497 participants
were included.
HLA-B allotypes were assigned by DNA sequencing, begin-
ning with the amplification of genomic DNA using primers
that flank exons 2 and 3. Polymerase chain reaction products
were cleaned using Ampure (Beckman Coulter). The cleaned
products were cycle sequenced on an ABI 9700. The cycle se-
quenced products were cleaned using CleanSEQ (Beckman Coul-
ter) and then run on an ABI Prism 3730. Sequence analysis was
performed using Assign (Conexio Genomics).
The EIGENSTRAT method [10] was used to control for pop-
ulation stratification. Assessment of population structure in 616
African Americans by use of the EIGENSTRAT method resulted
in 73 statistically significant axes of stratification after the removal
of 35 population outliers. The first axis made a larger contri-
bution to the proportion of variation (0.6%) explained than the
contribution made by the second axis (0.2%) and reflected the
degree of African versus European ancestry in individuals. We
therefore used only the first axis as a covariate in our association
analyses, to control for population stratification.
Phenotype. Set point viral load was defined as (1) the mean
viral load for samples with 2 or more viral load values that
were collected at least 30 days apart, within 3 months to 3 years
after seroconversion, and were within a 1 log range, similar to
what was done in the previous study of determinants of set
point in participants of European ancestry [1], or (2) the first
available viral load within 3–12 months after seroconversion,
as long as there was a corresponding CD4+ T cell count of 1350
cells/mL. All viral loads were measured prior to the initiation
of antiretroviral therapy. Viral loads from the 2 definitions were
highly correlated ( ), and the first definition was pref-2r p 0.74
erentially used when sufficient data were available.
Statistical analysis. Viral load at set point was used as a
quantitative trait in a linear regression using additive allelic
effects. Because previous studies have found that sex and age
may be associated with viral load, these factors were used as
covariates in the model [11, 12]. The first EIGENSTRAT axis
was used to control for population stratification, and the co-
hort was also included in the model because of baseline dif-
ferences between the 2 groups. Individual regressions for each
SNP were performed using PLINK software (version 1.06) [13,
14]. The Bonferroni correction was used to control for mul-
tiple comparisons. Associations for which were8P ! 5 10
considered to have genome-wide statistical significance.
All HLA-B allotypes were tested for association with viral
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Table 3. Major Histocompatibility Complex (MHC) Variants and Functional Variants That Are Associated with Viral Load Set Point
in African Americans ( )np 515
SNP Overall rank P Gene Type Frequency
Top 10 SNPs in the MHC region
rs2523608 2 62.29 10 HLA-B Intronic 0.366
rs34548063 23 51.57 10 STK19 Stop gained 0.028
rs2523933 29 52.03 10 HLA-W Intergenic 0.205
rs2844538 53 55.07 10 ZDHHC20P2 Downstream 0.492
rs2596503 81 58.15 10 HLA-B Downstream 0.162
rs9266689 96 59.86 10 ZDHHC20P2 In noncoding gene 0.485
rs4151650 99 41 10 CFB, C2 Synonymous coding 0.030
rs1736936 99 41 10 HLA-G Upstream 0.492
rs9378200 150 42 10 UQCRHP Intergenic 0.013
rs4713213 150 42 10 OR5V1, OR12D3 Intronic 0.331
Top 10 functional SNPs
rs34548063 23 51.57 10 STK19 Stop gained 0.028
rs1034405 91 59.65 10 C3orf18 Nonsynonymous coding 0.332
rs4838865 99 41 10 TUBGCP6 Nonsynonymous coding 0.048
rs6542522 99 41 10 C2orf76 Nonsynonymous coding, splice site 0.196
rs2280801 332 44 10 BAT2 Nonsynonymous coding 0.012
rs13146272 332 44 10 CYP4V2 Nonsynonymous coding 0.394
rs2273549 332 0.0004 TCP11L1 Nonsynonymous coding 0.092
rs2278329 332 0.0004 OSMR Nonsynonymous coding 0.042
rs10423723 435 0.0005 AC020907.3a Nonsynonymous coding 0.625
rs7258700 435 0.0005 AC020907.3a Nonsynonymous coding 0.625
NOTE. Age, sex, cohort, and 1 statistically significant EIGENSTRAT axis were used as covariates. SNP, single-nucleotide polymorphism.
a Listed as transcript in Ensembl (July 2009).
load set point in a linear regression model and were also eval-
uated to determine whether they were responsible for associ-
ations observed for SNPs in the genome-wide SNP association
analyses.
RESULTS
From the DoD HIV NHS cohort, 487 participants met the
inclusion criteria and 471 were successfully genotyped. From
the MACS cohort, 158 participants met the inclusion criteria
and 145 were successfully genotyped. Thirty-five participants
were dropped from the analysis because of the EIGENSTRAT
correction for ancestry, and 66 participants were not included
because their viral load results did not meet the definition of
set point described in Methods, which left 515 participants in
the final data set. Table 1 shows the baseline characteristics of
participants in the DoD and MACS cohorts, as well as the Bead
Chips that were used for genotyping. There were more women
in the DoD cohort ( ), and participants in this cohortPp .006
were, on average, younger at seroconversion ( ); how-P ! .001
ever, there was no difference between the cohorts in mean set
point viral load ( ).Pp .13
No single SNP had a genome-wide statistically significant
association ( ) with viral load at set point. Table 28P ! 5 10
lists the top 20 genome-wide associations with set point, and
Table 3 lists the top 10 associations from the MHC region and
the top 10 functional SNPs that are associated with set point.
A functional SNP was defined as a SNP that would cause the
gain or loss of a stop codon, would cause a nonsynonymous
coding change, or occurred in a splice site.
The most statistically significant SNP in the MHC region for
association with viral load set point in this African American
cohort was rs2523608, located in the HLA-B gene (Pp
) (Figure 1A and Table 3). We found that the same62.3 10
SNP was also statistically significantly associated with HIV-1
set point in a large sample of individuals of European ancestry
( , corrected for age and sex) (Figure 1B). This6Pp 1.1 10
association remains nominally statistically significant (Pp
) after accounting for variants in the MHC region that.0083
were previously shown to be associated with HIV-1 outcomes
(rs2395029, rs9264942, and rs9261174) and 12 statistically sig-
nificant EIGENSTRAT axes to control for population stratifi-
cation in this cohort.
The rs2523608 variant is located in intron 5 (according to
Ensembl transcript ENST00000376228), which is 1100 base
pairs from the nearest exon. Analysis of the HLA-B allotypes
from 285 genotyped study participants showed that this as-
sociation was due to the association between rs2523608 and
HLA-B*5703 ( ; ). The degree of linkage dis-′ 2D p 1 r p 0.075
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Table 4. Top Associations between HLA-B Allotypes and
Human Immunodeficiency Virus Type 1 Set Point (np
)285
Allotype Rank P Frequency
HLA-B*5703 1 5.6  1010 0.040
HLA-B*3910 2 0.00032 0.006
HLA-B*1517 3 0.00040 0.006
HLA-B*4501 4 0.00084 0.062
HLA-B*1302 5 0.020 0.005
HLA-B*580101 6 0.021 0.016
HLA-B*5802 7 0.022 0.040
HLA-B*4201 8 0.022 0.040
HLA-B*140201 9 0.024 0.020
HLA-B*1801 10 0.025 0.016
NOTE. Age, sex, cohort, and 1 statistically significant EIGENSTRAT
axis were used as covariates.
equilibrium can be quantified using the D′ statistic [15]. This
statistic compares the ancestral recombination patterns be-
tween 2 variants by standardizing allele frequencies. A value of
indicates that 1 variant always appears on the back-′D p 1
ground of the other. On the other hand, the r2 statistic is sen-
sitive to allele frequency differences and assesses the degree to
which the 2 variants appear together [16, 17]. When considered
alone, HLA-B*5703 had by far the strongest association with
viral load set point of any HLA-B allotype, showing genome-
wide statistical significance ( , with age, sex, co-10Pp 5.6 10
hort, and 1 EIGENSTRAT axis as covariates) (Table 4 and Fig-
ure 1C). Moreover, when HLA-B*5703 was included as a
covariate, it was able to account for the effect of the rs2523608
genotype. This analysis shows that HLA-B*5703 is the most
important common variant in influencing viral load in African
Americans, explaining ∼10% of the variation in viral load set
point in this data set, with an allele frequency of ∼4.0%.
CNV analysis. There were 8724 SNPs that showed evidence
of a duplication and 16,778 SNPs that showed evidence of a
deletion. The CNV calls for each SNP were then run as geno-
types in a regression using an additive genetic model, testing
for association with HIV-1 set point. Sex, cohort, and the first
EIGENSTRAT axis were used as covariates. After a Bonferroni
correction was applied ( for duplications and6 66 10 3 10
for deletions), no SNPs reached genome-wide statistical signifi-
cance for either deletions or duplications. Furthermore, when
the association results from these 2 models were compared, there
was no SNP associated with both deletions and duplications for
which .P ! .05
Association with previously implicated variants. We also
analyzed genetic variants that had previously been shown to have
an effect on HIV-1 set point. First, we tested the association with
rs2395029, a nonsynonymous SNP in the HCP5 gene that is a
tag for the functional allele HLA-B*5701, and found this SNP
to show a weak association with viral load set point ( )Pp .030
(Table 5). This SNP has a very low minor allele frequency in
African Americans (minor allele frequency, 0.008) because of its
virtual absence in West African populations. Therefore, the power
to detect an association in this cohort is only 81% at ,P ! .05
assuming that the effect size in our cohort is comparable to that
seen for individuals of European descent [1].
We then tested the association with rs9264942, a CrT poly-
morphism that is 35 kilobases upstream of the HLA-C gene.
This SNP itself is not causal, but it is a tagging SNP for an
unknown causal variant or variants. We observed a weak as-
sociation between rs9264942 and set point in African Ameri-
cans ( ) (Table 5).Pp .018
We also tested the associations between viral load at set
point and rs9261174, a SNP located near the ZNRD1 gene
in the MHC region, and CCR5-D32, a 32–base pair deletion
in the CCR5 gene (rs333) that is rare in non-European pop-
ulations. In our African American cohort, neither rs9261174
( ) nor CCR5-D32 ( ) showed an associationPp .352 Pp .484
with viral load at set point (Table 5).
DISCUSSION
To our knowledge, this was the first genome-wide association
study on HIV-1 outcomes to be performed among an African
American cohort, the majority of whom were infected with
HIV-1 subtype B. We have shown that the intronic SNP
rs2523608, the top associated SNP in the MHC region, is tag-
ging HLA-B*5703. The value of D′ for the association between
rs2523608 and HLA-B*5703 is 1, and a regression model shows
that the HLA-B*5703 genotype is able to account for the effect
of this intronic SNP. HLA-B*5703 is strongly associated with
viral load at set point and reached whole-genome statistical
significance in the subset of samples for which HLA-B allo-
type data were available ( , in a model that al-10Pp 5.6 10
so included age, sex, cohort, and the first EIGENSTRAT axis;
).np 285
HLA-B*5701 is an important mechanism of HIV-1 control
in the European population. It had an allele frequency of ∼6.1%
in a European population, but it was not observed in a Yoruban
population [18]. Its close relative HLA-B*5703 was absent in
a European population, but HLA-B*5703 had an allele fre-
quency of ∼5.8% in a Yoruban population [18]. Here, we have
shown that African American individuals who have HLA-
B*5703 also show improved viral control, of a magnitude sim-
ilar to that afforded by HLA-B*5701 in people of European
descent. Thus, our results indicate that the general mechanism
of genetic control of HIV-1 in African Americans is similar to
that in Europeans: HLA-B*5701 accounts for ∼6% of the ob-
served variation in viral load set point in Europeans [7], and
HLA-B*5703 accounts for ∼10% of the observed variation in
viral load set point in African Americans. There was also a
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Table 5. Association Outcomes for Genetic Variants That Have Been Previously Reported to Be Associated with
Human Immunodeficiency Virus Type 1 Set Point or Disease Progression
SNP Gene Type
African Americans European Americans
No.
of patients P a MAF
No.
of patients P b MAF
rs2395029 HCP5 Nonsynonymous 513 0.030 0.008 2362 354.5 10 0.048
rs9264942 HLA-C Upstream 515 0.018 0.286 2362 325.9 10 0.412
rs9261174 ZNRD1 Intergenic 511 0.352 0.245 2362 41.1 10 0.141
rs333 (D32) CCR5 Genic deletion 502 0.484 0.017 2333 101.7 10 0.099
NOTE. MAF, minor allele frequency; SNP, single-nucleotide polymorphism.
a P values are corrected for age, sex, cohort, and 1 statistically significant EIGENSTRAT axis.
b P values are corrected for age, sex, and 12 statistically significant EIGENSTRAT axes.
Figure 2. Comparison of the mean linkage disequilibrium in the major histocompatibility complex region between persons of European and African
American ancestry. The mean values of D ′ and r 2 are both smaller in the African American genome than in the European genome. Kb, kilobase.
small contribution to HIV-1 control by HLA-B*5701 (fre-
quency, 0.3%) in our African American data set, because of
admixture.
We also found that HLA-B*3910 and HLA-B*1517, in addition
to HLA-B*5703, may be playing a lesser role in viral control,
although additional studies would be needed to confirm these
observations. This pattern was similar to that observed in people
of European descent, among whom HLA-B*5701 is the largest
determinant of HIV-1 control but other HLA-B alleles (HLA-
B*27, HLA-B*35, and others) also play a role [7]. The effects of
the alleles that we have identified are further supported by an
analysis of the MHC region that was conducted in southern
African populations infected with HIV-1 subtype C, in which
HLA-B*5703 was found to be the HLA class I allele most strong-
ly associated with a decreased viral load set point [3, 19], with
a weaker contribution by HLA-B*39 [19].
We found a reduced or absent association with viral load set
point when we explicitly checked variants that had been shown
to be associated with set point in a cohort of patients of Eu-
ropean descent. Similar outcomes were seen in Shrestha et al
[4], who saw a reduced association between rs9264942 and set
point and no association between rs2395029 and set point. Our
sample size was 14 times larger than that in Shrestha et al [4]
and revealed only weak associations between both variants and
set point. So although both rs9264942 and rs2395029 are de-
finitively associated with viral load set point in European pop-
ulations, neither study was able to replicate these associations
in an African American cohort.
It is worth noting that it is only the HLA-B*5701 association
in the previous study [1] for which the causal site is thought
to have been identified. In the cases of rs9264942 and
rs9261174, it is likely that the associated variants are not
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themselves causal but rather markers of an as yet unidenti-
fied causal site or sites. It may therefore not be a coincidence
that the HLA-B*57 association is the only one to show an ef-
fect in African Americans that is similar to that shown in in-
dividuals of European ancestry. For the other 2 associations,
the different and generally lower linkage disequilibrium in this
region in African Americans (Figure 2) could mean that the
causal sites are no longer being tagged by these variants.
A potential limitation of this study is that HIV-infected per-
sons with rapid disease progression may have been excluded.
Rapid progressors may not have had many research visits and
therefore may not have had enough cells in the repository to
be included in this study. In addition, because of their rapid
disease progression, they may not have had available viral load
measurements that satisfied the definition of set point. Ap-
proximately 10% of the participants in this study progressed
to a CD4+ cell count of !200 cells/mm3 within 2 years after
seroconversion; therefore, there were at least some rapid pro-
gressors included in this study.
Earlier studies have likewise suggested that HLA-B*5703 may
also be involved in HIV-1 control in African Americans, but
our study shows that it is indeed the most statistically significant
common genetic factor affecting early viral control in this pop-
ulation. By using a genome-wide scan to implicate another allele
of HLA-B*57 in HIV-1 control, in an ancestral background that
was entirely different from that where this association had pre-
viously been observed, we provide further support for the im-
portant role played by HLA-B*57 in HIV-1 control and the
decreased fitness level of the viral mutants that are selected for
by HLA-B*57. Given the increased burden of disease in African
and African American populations and the paucity of common
variants that clearly influence HIV-1 control, it is important to
continue to investigate rare variants that may function specif-
ically in these populations.
MEMBERS OF THE INFECTIOUS DISEASE
CLINICAL RESEARCH PROGRAM HIV WORKING
GROUP
M. Polis, J. Powers, and E. Tramont (National Institute of Al-
lergy and Infectious Diseases, Bethesda, MD); J. Maguire (Naval
Medical Center, Portsmouth, VA; M. Bavaro, N. Crum-Cian-
flone, and H. Chun (Naval Medical Center, San Diego, CA);
C. Decker, A. Ganesan, and T. Whitman (National Naval Med-
ical Center, Bethesda, MD); W. Bradley, V. Marconi, S. Merritt,
and J. Okulicz (San Antonio Military Medical Center, San An-
tonio, TX); A. Johnson (Tripler Army Medical Center, Hon-
olulu, HI); B. Agan (Uniformed Services University of the
Health Sciences, Bethesda, MD); C. Eggleston, L. Jagodzinski,
R. O’Connell, and S. Peel (Walter Reed Army Institute of Re-
search, Rockville, MD); C. Hawkes, G. Wortmann, and M.
Zapor (Walter Reed Army Medical Center, Washington, DC);
and L. Eberly and A. Lifson (University of Minnesota).
MULTICENTER AIDS COHORT STUDY CENTERS
The Johns Hopkins Bloomberg School of Public Health, Bal-
timore, MD (J. Margolick); Howard Brown Health Center and
Northwestern University Medical School, Chicago, IL (J. Phair);
University of California, Los Angeles, CA (R. Detels); University
of Pittsburgh, Pittsburgh, PA (C. Rinaldo); and Data Analysis
Center, Baltimore, MD (L. Jacobson).
Acknowledgments
The content of this publication is the sole responsibility of the authors
and does not necessarily reflect the views or policies of the National In-
stitutes of Health or the Department of Health and Human Services, or
of the Department of Defense or the Department of the Army, Navy, or
Air Force. Mention of trade names, commercial products, or organizations
does not imply endorsement by the United States government.
We thank all of the patients in the Department of Defense HIV Natural
History Study, Multicenter AIDS Cohort Study, and European Center for
HIV/AIDS Vaccine Immunology (Euro-CHAVI) cohorts.
References
1. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study
of major determinants for host control of HIV-1. Science 2007; 317:
944–947.
2. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly
associated with restriction of virus replication in a subgroup of HIV-
infected long term nonprogressors. Proc Natl Acad Sci U S A 2000;
97:2709–2714.
3. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-
B in mediating the potential co-evolution of HIV and HLA. Nature
2004; 432:769–775.
4. Shrestha S, Aissani B, Song W, Wilson CM, Kaslow RA, Tang J. Host
genetics and HIV-1 viral load set-point in African-Americans. AIDS
2009; 23:673–677.
5. Shrestha S, Strathdee SA, Galai N, et al. Behavioral risk exposure and
host genetics of susceptibility to HIV-1 infection. J Infect Dis 2006; 193:
16–26.
6. Lama J, Planelles V. Host factors influencing susceptibility to HIV in-
fection and AIDS progression. Retrovirology 2007; 4:52.
7. Fellay J, Ge D, Shianna KV, et al. Common genetic variation and the
control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.
8. Wang K, Li M, Hadley D, et al. PennCNV: an integrated hidden Markov
model designed for high-resolution copy number variation detection in
whole-genome SNP genotyping data. Genome Res 2007; 17:1665–1674.
9. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts
hepatitis C treatment-induced viral clearance. Nature 2009; 461:399–
401.
10. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich
D. Principal components analysis corrects for stratification in genome-
wide association studies. Nat Genet 2006; 38:904–909.
11. Napravnik S, Poole C, Thomas JC, Eron JJ. Gender difference in HIV
RNA levels: a meta-analysis of published studies. J Acquir Immune
Defic Syndr 2002; 31:11–19.
12. Quinn TC, Wawer MJ, Sewankwambo N, et al. Viral load and het-
erosexual transmission of human immunodeficiency virus type 1. N
Engl J Med 2000; 342:921–929.
13. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a toolset for whole-
 at UniversitÃ© & EPFL Lausanne on April 11, 2011
jid.oxfordjournals.org
D
ow
nloaded from
 
HIV Control in African Americans • JID 2010:201 (15 April) • 1149
genome association and population-based linkage analysis. Am J Hum
Genet 2007; 81:559–575.
14. Purcell S. PLINK: whole genome association analysis toolset. Harvard
University Web site. http://pngu.mgh.harvard.edu/purcell/plink/. Up-
dated 10 October 2009. Accessed 15 June 2009.
15. Lewontin RC. The interaction of selection and linkage. I. General con-
siderations; heterotic models. Genetics 1964; 49:49–67.
16. Kruglyak L. Prospects for whole-genome linkage disequilibrium map-
ping of common disease genes. Nature Genet 1999; 22:139–144.
17. Pritchard JK, Przeworski M. Linkage disequilibrium in humans: models
and data. Am J Hum Genet 2001; 69:1–14.
18. de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and
SNP haplotype map for disease association studies in the extended
human MHC. Nat Genet 2006; 38:1166–1172.
19. Tang J, Tang S, Lobashevsky E, et al. Favorable and unfavorable HLA
class I alleles and haplotypes in Zambians predominantly infected with
clade C human immunodeficiency virus type 1. J Virol 2002; 76:8276–
8284.
 at UniversitÃ© & EPFL Lausanne on April 11, 2011
jid.oxfordjournals.org
D
ow
nloaded from
 
